Chemotherapy of Leishmaniasis.
Annual progress rept. no. 8, 1 Jan-31 Dec 82,
GEORGIA UNIV ATHENS
Pagination or Media Count:
Three-day infections of L. donovani in the golden hamster primary visceral test system were used to test a total of 381 compounds 353 new compounds and 24 compounds requiring additional testing for antileishmanial activity against visceral leishmaniasis and 19 day infections of L. braziliensis panamensis in the golden hamster primary cutanious test system were used to test s total of 217 different compounds for activity against cutaneous infections. One hundred and twenty-seven of the 381 compounds tested in the primary visceral test system were observed to have significant suppressive activity against L. donovani at one or more drug dosage levels. At total of twenty-six of these compounds has sufficient antileishmanial activity to warrant the calculation of a Glucantime Index. Twenty of these had suppressive activity greater than that of the reference compound, Glucantime, two had activity equal to Glucantime, and four had activity less than Glucantime. Fifty-six of the 217 compounds tested in the primary cutaneous test system were noted to have significant suppressive activity against L. braziliensis panamensis at one or more drug dosage levels. One of these has antileishmanial activity sufficient for the calculation of a Glucantime Index. Special studies were conducted in which attempts were made to establish the optimal treatment regimen using WR 6026 and Formycin B. No appreciable difference was noted in the percent suppression of parasites when a given dosage was administered in a single treatment or in 24, 8, or 16 treatments. Keywords Liposome-encapsulated drugs.
- Medicine and Medical Research